These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 7505224)
1. Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Doxazosin Study Groups. Janknegt RA; Chapple CR Eur Urol; 1993; 24(3):319-26. PubMed ID: 7505224 [TBL] [Abstract][Full Text] [Related]
2. Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men. Kirby RS Urology; 1995 Aug; 46(2):182-6. PubMed ID: 7542819 [TBL] [Abstract][Full Text] [Related]
3. A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Chapple CR; Carter P; Christmas TJ; Kirby RS; Bryan J; Milroy EJ; Abrams P Br J Urol; 1994 Jul; 74(1):50-6. PubMed ID: 7519112 [TBL] [Abstract][Full Text] [Related]
4. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia. Andersen M; Dahlstrand C; Høye K Eur Urol; 2000 Oct; 38(4):400-9. PubMed ID: 11025377 [TBL] [Abstract][Full Text] [Related]
5. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. Fawzy A; Braun K; Lewis GP; Gaffney M; Ice K; Dias N J Urol; 1995 Jul; 154(1):105-9. PubMed ID: 7539853 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of doxazosin in normotensive and hypertensive patients with benign prostatic hyperplasia. Kirby RS Scand J Urol Nephrol Suppl; 1995; 168():29-33. PubMed ID: 7541549 [TBL] [Abstract][Full Text] [Related]
7. Long-term (4 year) efficacy and tolerability of doxazosin for the treatment of concurrent benign prostatic hyperplasia and hypertension. Fawzy A; Hendry A; Cook E; Gonzalez F Int J Urol; 1999 Jul; 6(7):346-54. PubMed ID: 10445304 [TBL] [Abstract][Full Text] [Related]
8. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. Gillenwater JY; Conn RL; Chrysant SG; Roy J; Gaffney M; Ice K; Dias N J Urol; 1995 Jul; 154(1):110-15. PubMed ID: 7539854 [TBL] [Abstract][Full Text] [Related]
9. Tolerability of alpha-blockade with doxazosin as a therapeutic option for symptomatic benign prostatic hyperplasia in the elderly patient: a pooled analysis of seven double-blind, placebo-controlled studies. Kaplan SA; D'Alisera PM J Gerontol A Biol Sci Med Sci; 1998 May; 53(3):M201-6. PubMed ID: 9597052 [TBL] [Abstract][Full Text] [Related]
10. A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: the Hypertension and BPH Intervention Trial (HABIT). Guthrie RM; Siegel RL Clin Ther; 1999 Oct; 21(10):1732-48. PubMed ID: 10566569 [TBL] [Abstract][Full Text] [Related]
11. Profile of doxazosin in patients with benign prostatic hyperplasia. Janknegt RA Scand J Urol Nephrol Suppl; 1995; 168():21-7. PubMed ID: 7541548 [TBL] [Abstract][Full Text] [Related]
12. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability]. Gratzke P; Kirby RS Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491 [TBL] [Abstract][Full Text] [Related]
13. Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group. Lepor H; Kaplan SA; Klimberg I; Mobley DF; Fawzy A; Gaffney M; Ice K; Dias N J Urol; 1997 Feb; 157(2):525-30. PubMed ID: 8996348 [TBL] [Abstract][Full Text] [Related]
14. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. Kirby RS; Andersen M; Gratzke P; Dahlstrand C; Høye K BJU Int; 2001 Feb; 87(3):192-200. PubMed ID: 11167641 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392 [TBL] [Abstract][Full Text] [Related]
16. Effect of doxazosin on the symptoms of benign prostatic hyperplasia: results from three double-blind placebo-controlled studies. Mobley DF; Kaplan S; Ice K; Gaffney M; Dias N Int J Clin Pract; 1997; 51(5):282-8. PubMed ID: 9489085 [TBL] [Abstract][Full Text] [Related]
17. Effects of doxazosin in men with benign prostatic hyperplasia: urodynamic assessment. Ozbey I; Aksoy Y; Polat O; Biçgi O; Demirel A; Okyar G Int Urol Nephrol; 1999; 31(4):471-9. PubMed ID: 10668942 [TBL] [Abstract][Full Text] [Related]
18. The treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 80 years. Kaplan SA; Te AE; Ikeguchi E; Santarosa RP Br J Urol; 1997 Dec; 80(6):875-9. PubMed ID: 9439400 [TBL] [Abstract][Full Text] [Related]
19. Urodynamic effects of doxazosin in men with lower urinary tract symptoms and benign prostatic obstruction. Results from three double-blind placebo-controlled studies. Abrams P Eur Urol; 1997; 32(1):39-46. PubMed ID: 9266230 [TBL] [Abstract][Full Text] [Related]
20. [Single-blind study of the effect of doxazosin mesylate in benign prostatic hypertrophy]. Siracusano S; Paoni A; Tomasi PA; Deriu M; Trombetta C; Belgrano E Prog Urol; 1994 Dec; 4(6):1017-21. PubMed ID: 7533030 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]